Real Metformin Weight Loss Reviews: What to Expect

Metformin produces modest but real weight loss for most people who take it, typically in the range of a few percent of body weight rather than the dramatic drops seen with newer injectable medications. In the largest and longest study tracking this question, people on metformin maintained about 2% more weight loss than those on placebo over a decade of follow-up. That number sounds small on paper, but the story is more interesting than the headline figure suggests, and what you experience depends heavily on your starting point, your dose, and why you’re taking it.

How Much Weight Loss to Realistically Expect

The best long-term data comes from the Diabetes Prevention Program (DPP), a major trial that followed thousands of people with prediabetes for over 15 years. During the initial treatment phase, metformin users lost more weight than the placebo group, and that gap persisted. After 10 years, the metformin group had maintained about 2% more weight loss than placebo, and the degree of loss was directly tied to how consistently people took the drug.

What’s striking is the longer-term follow-up data from that same study. Among people who lost at least 5% of their body weight in the first year, more than half of those in the metformin group kept that loss off across the full 14-year follow-up period. By contrast, only about 42% of placebo participants managed the same. Metformin participants maintained an average of about 6% weight loss relative to baseline between years 6 and 15, compared to roughly 3% for the placebo group.

For people without diabetes, a systematic review and meta-analysis found that metformin significantly reduced BMI and showed a tendency to reduce overall body weight in overweight and obese populations. The effects were meaningful but not transformative on their own.

So what does this translate to in practical terms? For someone weighing 200 pounds, a sustained 2-3% loss means roughly 4 to 6 pounds. For someone who responds well and maintains adherence over years, the numbers can reach 5-6% of body weight, or 10 to 12 pounds. These are not the kinds of results that make before-and-after photos dramatic, but they are the kinds that can shift metabolic markers, reduce waist circumference, and keep creeping weight gain in check over time.

Why Metformin Causes Weight Loss in the First Place

Metformin was developed to lower blood sugar, not to cause weight loss. It works primarily by dialing down the liver’s production of glucose and improving how well your body responds to insulin.

⁴ The weight loss was essentially a welcome side effect that researchers noticed and then investigated more closely.

The appetite-suppression piece of the puzzle became clearer when researchers discovered that metformin raises levels of a hormone called GDF15 in the blood. Two independent randomized controlled trials confirmed that metformin increases circulating GDF15, a peptide that acts on receptors in the brainstem to reduce food intake and lower body weight.

⁵ Mouse studies showed that when the GDF15 system was knocked out, metformin’s effects on food intake and body weight disappeared entirely.

⁶

There are additional mechanisms at play. Metformin influences gut hormones like GLP-1 (the same family of hormones targeted by semaglutide and similar drugs), alters the bile acid pool in the intestines, and changes the composition of gut bacteria.

⁷ There is also evidence that metformin promotes the activity of brown adipose tissue, the calorie-burning fat that generates heat rather than storing energy.

⁸

The practical upshot of all this is that metformin chips away at weight through several channels at once: you tend to feel a bit less hungry, your body handles insulin more efficiently so less energy gets stored as fat, and your gut environment shifts in ways that favor slightly lower calorie absorption. No single mechanism produces a blockbuster effect, but together they add up to a modest, persistent nudge.

The Side Effects That Shape Your Experience

Almost every person who has taken metformin has a gastrointestinal story to tell. Nausea, diarrhea, bloating, and stomach cramps are common, especially in the first few weeks. These side effects are so predictable that doctors almost always start patients at a low dose and gradually increase it. For some people, the GI symptoms never fully resolve and become the reason they stop the medication.

In one survey of patients taking metformin for polycystic ovary syndrome (PCOS), about 22 out of the group discontinued the drug specifically because of gastrointestinal complaints, with an additional 8 stopping because they felt the medication wasn’t helping enough.

⁹

Ironically, the GI side effects themselves contribute to the weight loss picture. When eating makes you feel queasy or gives you diarrhea, you naturally eat less. Some of the early weight loss people report on metformin is likely driven as much by these symptoms as by any metabolic mechanism. As your body adjusts and the side effects fade (which they usually do after 2 to 4 weeks), the rate of weight loss can slow down, and that transition catches some people off guard.

Extended-Release vs. Immediate-Release Formulations

If side effects are shaping your experience with metformin, the formulation you’re on matters. The extended-release (XR) version releases the drug more slowly through your digestive system, and the difference in tolerability is significant. In one six-month comparison, about 45% of patients on the immediate-release version reported GI side effects, compared to roughly 25% on extended-release.

¹⁰ Patients on XR also reported fewer therapy interruptions due to stomach upset. A separate study confirmed that adverse events were more common with the immediate-release formula at both three and six months, and patient satisfaction scores were higher with the extended-release version.

¹¹

If you’re struggling with side effects on immediate-release metformin, switching to XR is one of the first things worth discussing with your doctor. The blood sugar control is comparable between formulations, so you’re not trading effectiveness for comfort. Taking the medication with food, particularly dinner, also helps reduce stomach upset regardless of which version you’re on.

PCOS and Metformin Weight Loss

Polycystic ovary syndrome is one of the most common reasons women are prescribed metformin off-label. The relationship between PCOS, insulin resistance, and weight gain is tight, and metformin addresses the insulin resistance that drives much of the syndrome’s metabolic dysfunction. A large meta-analysis of randomized controlled trials found that metformin reduced BMI by about half a unit more than placebo in women with PCOS, along with improvements in insulin resistance, fasting glucose, and cholesterol levels. The trade-off was a notable increase in mild GI side effects.

¹²

Dose may matter here. In a study comparing 1,500 mg and 2,550 mg daily doses in obese women with PCOS, both groups lost weight, but the higher dose produced more weight loss among obese (as opposed to morbidly obese) women, with losses of about 3.6 kg versus 1.5 kg. In the morbidly obese subgroup, both doses produced similar results of about 3.8 to 3.9 kg.

¹³

A recent comprehensive review puts it bluntly: in women with PCOS, metformin improves insulin resistance, menstrual regularity, and androgen levels, particularly in those with obesity or insulin resistance. But it is not effective as a first-line therapy for weight loss alone.

¹⁴ The weight loss is a benefit that comes alongside the metabolic improvements, not the primary reason to take it.

Antipsychotic-Induced Weight Gain

One of the less discussed but increasingly well-studied uses of metformin is preventing or reversing weight gain caused by antipsychotic medications. These drugs can cause substantial weight gain, sometimes 10% of body weight or more, and metformin is currently the only pharmacological agent with demonstrated effectiveness for preventing it. When started alongside an antipsychotic, metformin reduced weight gain by about 4 kg compared to controls.

¹⁵

In a randomized trial comparing interventions for people already experiencing antipsychotic-related weight gain, metformin alone produced about a 5% decrease in body weight over 12 weeks, while those on placebo continued gaining. Combining metformin with lifestyle changes was even better, producing about a 7% decrease.

¹⁶ Retrospective data from clinical practice has confirmed this pattern: patients on antipsychotics alone gained weight, while those also taking metformin showed a reduction in that tendency.

¹⁷

This is arguably where metformin’s weight effects are most clinically meaningful. The weight gain from antipsychotics is a leading reason people stop taking medications they genuinely need for their mental health, so even a modest counterweight can make a real difference in treatment adherence.

How Metformin Compares to GLP-1 Drugs

Anyone researching metformin for weight loss in 2024 or 2025 inevitably encounters semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound). The comparison is not particularly close. In a pilot study of patients with antipsychotic-induced weight gain, semaglutide produced about 4.5 kg of weight loss over 16 weeks compared to 2.9 kg with metformin. Semaglutide reduced BMI by about twice as much and waist circumference by about double as well. Interestingly, the between-group differences were not statistically significant in this small study, but the trend was consistent.

¹⁸

In broader obesity trials (not limited to antipsychotic populations), GLP-1 drugs routinely produce 10-15% body weight loss, dwarfing metformin’s typical 2-5%. But metformin costs a fraction of the price, has decades of safety data, is available as a generic, and doesn’t require injections. For someone who cannot access or tolerate GLP-1 medications, or who needs a gentle long-term option rather than aggressive weight reduction, metformin fills a different niche. It’s less a competitor to these newer drugs and more a different tool for a different job.

What Happens When You Stop

Weight regain after stopping metformin is real and worth planning for. A study of women with PCOS found that those who had only been on metformin for a short time gained a significant amount of weight after stopping, going from a median of 92 kg to 96 kg. Even long-term users trended upward, though the increase wasn’t as sharp. More women in the long-term group managed to maintain stable weight, but only about 27% of them, compared to 15% of short-term users.

¹⁹

This pattern aligns with what the DPP data showed about adherence: the weight loss benefit tracked directly with how consistently people continued taking the drug.

¹ Metformin is not a one-and-done intervention. It works while you take it, and the benefits fade when you stop. This isn’t unique to metformin — the same is true of GLP-1 drugs, blood pressure medications, and most chronic disease treatments. But it’s worth understanding upfront so you don’t frame it as a short course that “resets” your metabolism.

Exercise, Diet, and Whether Metformin Adds to Them

The DPP trial originally had three arms: metformin, intensive lifestyle intervention (diet and exercise coaching), and placebo. In the early years, the lifestyle group actually lost more weight than the metformin group, though metformin users caught up over the long term as the lifestyle group partially regained.

There’s a wrinkle in how metformin interacts with exercise specifically. A study of people with prediabetes found that exercise alone, metformin alone, and the combination all improved insulin sensitivity. But the combination did not produce a clearly additive benefit. In fact, the exercise-only group showed a somewhat larger improvement in insulin sensitivity than the group that exercised while also taking metformin, hinting that metformin might slightly blunt some of the metabolic adaptations that exercise normally triggers. The differences weren’t statistically significant, but the pattern was consistent enough to be notable.

What this means practically is that metformin is not a substitute for lifestyle changes, and stacking it on top of a solid exercise routine may not double your results. Where metformin seems to shine is in the long game: helping people maintain weight loss over years, even when the initial intensity of diet and exercise efforts fades. The DPP data showed that metformin participants maintained their loss more durably than either the lifestyle or placebo groups across the full follow-up period.

Vitamin B12 and Long-Term Use

If you plan to take metformin for years, there’s one nutritional concern that gets too little attention in casual discussions. Long-term metformin use is linked to lower vitamin B12 levels. In the DPP study, combined low and borderline-low B12 was about twice as common in the metformin group at 5 years (about 19% versus 10% in placebo), and the risk increased with each additional year of use.

²⁰ Peripheral neuropathy was more common in metformin users who had low B12.

A separate analysis found that patients with B12 deficiency had substantially higher rates of peripheral neuropathy (about 36% versus 15%) and macrocytic anemia (about 12% versus 4%) compared to those with sufficient B12 levels.

²¹ The relationship between high-dose, long-duration metformin use and impaired B12 status has been confirmed across multiple studies and meta-analyses.

²²

The fix is straightforward: periodic B12 monitoring and supplementation if levels drop. But many people taking metformin off-label for weight loss may not get the same follow-up bloodwork that diabetic patients routinely receive. If you’re taking metformin for any reason and plan to stay on it for more than a year or two, asking your doctor to check B12 levels periodically is a small effort that can prevent a real problem. Tingling or numbness in your hands and feet, unusual fatigue, and difficulty concentrating can all signal B12 deficiency, and they’re easy to miss or attribute to other causes.

1
PubMed Central. Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study
2
PubMed Central. Long-term Weight Loss with Metformin or Lifestyle Intervention in the Diabetes Prevention Program Outcomes Study
3
PubMed. Role of metformin in overweight and obese people without diabetes: a systematic review and network meta-analysis
4
PubMed. Metformin: an update
5
Nature. GDF15 mediates the effects of metformin on body weight and energy balance
6
PubMed. Metformin-induced increases in GDF15 are important for suppressing appetite and promoting weight loss
7
Nature Reviews Endocrinology. Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus
8
Endocrinology and Metabolism. Metformin and Adipose Tissue: A Multifaceted Regulator in Metabolism, Inflammation, and Regeneration
9
Endocrine Abstracts. Patient reported outcomes for the use of metformin in polycystic ovarian syndrome (PCOS)
10
PubMed Central. Comparative effectiveness of immediate-release and extended-release metformin on gastrointestinal tolerability, quality of life, and treatment satisfaction: A prospective cohort study
11
PubMed Central. Effects of metformin extended release compared to immediate release formula on glycemic control and glycemic variability in patients with type 2 diabetes
12
European Journal of Endocrinology. The impact of metformin with or without lifestyle modification versus placebo on polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials
13
The Journal of Clinical Endocrinology & Metabolism. Metformin and Weight Loss in Obese Women with Polycystic Ovary Syndrome: Comparison of Doses
14
PubMed Central. Metformin use in women with polycystic ovary syndrome (PCOS): Opportunities, benefits, and clinical challenges
15
PubMed Central. Metformin for the Prevention of Antipsychotic-Induced Weight Gain: Guideline Development and Consensus Validation
16
JAMA. Lifestyle Intervention and Metformin for Treatment of Antipsychotic-Induced Weight Gain: A Randomized Controlled Trial
17
PubMed Central. The Association Between Antipsychotics and Weight Gain and the Potential Role of Metformin Concomitant Use: A Retrospective Cohort Study
18
PubMed Central. Management of obesity with semaglutide or metformin in patients with antipsychotic-induced weight gain (MOSA): a non-randomised open-label pilot study
19
PubMed Central. Effects of metformin withdrawal after long and short term treatment in PCOS: observational longitudinal study
20
PubMed Central. Long-term Metformin Use and Vitamin B12 Deficiency in the Diabetes Prevention Program Outcomes Study
21
European Journal of Cardiovascular Medicine. Vitamin B12 Deficiency in Long-Term Metformin users: Prevalence, Predictors, and Clinical Outcomes
22
PubMed Central. Long-term metformin therapy and vitamin B12 deficiency: An association to bear in mind